comprehensive
Previous article:
In age of alternative facts, a scholarly course on calling out crap
Next article: Medicare Advantage proposed rates disappoint insurers
Next article: Medicare Advantage proposed rates disappoint insurers
focus
hotspot
-
A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.
2025-09-28 19:10 -
A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.
2025-09-28 18:12 -
Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk
2025-09-28 18:02 -
What we’ve learned from the Aduhelm mess
2025-09-28 17:15 -
A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.
2025-09-28 17:06 -
Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more
2025-09-28 17:05